With the advancements in tumor molecular biology, treatments with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have provided patients with EGFR mutation-positive advanced lung cancer a longer progression-free survival, especially for patients with brain metastases from EGFR-mutated NSCLC who received erlotinib combined with whole brain radiotherapy (27, 28). The gene discussed is EGFR; the disease is lung cancer.